{"id":13046,"date":"2010-12-23T06:17:40","date_gmt":"2010-12-23T11:17:40","guid":{"rendered":"http:\/\/asweetlife.org\/?p=13046"},"modified":"2015-12-29T08:53:10","modified_gmt":"2015-12-29T13:53:10","slug":"new-novo-norkdisk-insulin-degludec-reduces-risk-of-nighttime-hypoglycaemia-new-studies-show","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=13046","title":{"rendered":"New Novo Nordisk Insulin Reduces Risk of Nighttime Hypoglycemia, New Studies Show"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/12\/NovoNordiskLogo3.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-13048 lazyload\" title=\"NovoNordiskLogo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/12\/NovoNordiskLogo3.png\" alt=\"\" width=\"151\" height=\"112\" \/><\/a>Novo Nordisk&#8217;s ultra long-acting basal insulin Degludec significantly reduces risk of hypoglycemia during the night compared to insulin glargine, according to two long-term studies. The company announced the clinical results from two 52-week phase 3a treat-to-target studies comparing Degludec to insulin glargine in basal-bolus treatment of type 1 and type 2 diabetes.<br \/> Basal-bolus treatment is comprised of treatment with long-acting (basal) insulin and a rapid-acting (bolus) insulin, and in both studies insulin aspart was used as the bolus insulin. These studies, as well as three additional studies reported today, are part of the largest clinical development program ever conducted for an insulin.<\/p>\n<p>In both the type 1 and the type 2 diabetes studies, patients showed improved blood glucose control. Average HbA1c levels improved by 1.2% in the type 2 diabetes study and by 0.4% in the type 1 study.<\/p>\n<p>Degludec also showed a lower risk of hypoglycemia compared to insulin glargine in both studies. And rates of confirmed nighttime hypoglycemia were reduced significantly, down by 25% in the type 2 study and 24% in the type 1 study compared to insulin glargine.<\/p>\n<p>Source: http:\/\/www.novonordisk.com\/press\/default.asp<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk&#8217;s ultra long-acting basal insulin Degludec significantly reduces risk of hypoglycemia during the night compared to insulin glargine, according to two long-term studies. The company announced the clinical results from two 52-week phase 3a treat-to-target studies comparing Degludec to insulin glargine in basal-bolus treatment of type 1 and type 2 diabetes&#8230;<\/p>\n","protected":false},"author":131,"featured_media":13048,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[264,1257],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New Novo Nordisk Insulin Degludec Reduces Risk of Nighttime Hypoglycaemia<\/title>\n<meta name=\"description\" content=\"Novo Nordisk&#039;s ultra long-acting basal insulin Degludec reduces risk of nighttime hypoglycemia, in type 1 and type 2 diabetics, compared to insulin glargine, long-term studies show.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=13046\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=13046\",\"url\":\"https:\/\/asweetlife.org\/?p=13046\",\"name\":\"New Novo Nordisk Insulin Degludec Reduces Risk of Nighttime Hypoglycaemia\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=13046#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=13046#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/12\/NovoNordiskLogo3.png\",\"datePublished\":\"2010-12-23T11:17:40+00:00\",\"dateModified\":\"2015-12-29T13:53:10+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Novo Nordisk's ultra long-acting basal insulin Degludec reduces risk of nighttime hypoglycemia, in type 1 and type 2 diabetics, compared to insulin glargine, long-term studies show.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=13046#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=13046\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=13046#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/12\/NovoNordiskLogo3.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/12\/NovoNordiskLogo3.png\",\"width\":215,\"height\":160,\"caption\":\"NovoNordiskLogo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=13046#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Novo Nordisk Insulin Reduces Risk of Nighttime Hypoglycemia, New Studies Show\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New Novo Nordisk Insulin Degludec Reduces Risk of Nighttime Hypoglycaemia","description":"Novo Nordisk's ultra long-acting basal insulin Degludec reduces risk of nighttime hypoglycemia, in type 1 and type 2 diabetics, compared to insulin glargine, long-term studies show.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=13046","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=13046","url":"https:\/\/asweetlife.org\/?p=13046","name":"New Novo Nordisk Insulin Degludec Reduces Risk of Nighttime Hypoglycaemia","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=13046#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=13046#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/12\/NovoNordiskLogo3.png","datePublished":"2010-12-23T11:17:40+00:00","dateModified":"2015-12-29T13:53:10+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Novo Nordisk's ultra long-acting basal insulin Degludec reduces risk of nighttime hypoglycemia, in type 1 and type 2 diabetics, compared to insulin glargine, long-term studies show.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=13046#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=13046"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=13046#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/12\/NovoNordiskLogo3.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/12\/NovoNordiskLogo3.png","width":215,"height":160,"caption":"NovoNordiskLogo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=13046#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"New Novo Nordisk Insulin Reduces Risk of Nighttime Hypoglycemia, New Studies Show"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/13046"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13046"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/13046\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/13048"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}